Semax Cognitive Research: Australian Overview
For laboratory research use only. Not for human use. Research use only.
Semax is a synthetic heptapeptide derived from the ACTH (adrenocorticotropic hormone) 4-10 fragment. It has been studied in preclinical and clinical research for its apparent effects on cognitive function, neuroprotection, and BDNF (brain-derived neurotrophic factor) expression. This guide covers the research landscape for Australian researchers.
What is Semax?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analogue of the ACTH 4-7 fragment, extended with a Pro-Gly-Pro sequence to improve stability. It was developed in Russia in the 1980s and has been used clinically in Russia and Ukraine for neurological conditions, though it is not TGA-approved in Australia.
Semax is available in both injectable and nasal spray formulations. The nasal spray format has been studied for its bioavailability via the olfactory pathway, which may allow direct delivery to the central nervous system. For laboratory research use only in Australia.
Cognitive and Neuroprotective Research
Preclinical studies have examined Semax's apparent effects on BDNF expression, neurogenesis, and cognitive performance in rodent models. A 2007 study in the Journal of Neurochemistry examined Semax's apparent upregulation of BDNF and its receptor TrkB in rat hippocampal tissue, which is associated with synaptic plasticity and memory formation.
Research has also examined Semax's apparent neuroprotective effects in stroke and ischaemia models. Rodent studies have observed apparent reduction in infarct volume and improved neurological outcomes following Semax administration in cerebral ischaemia models.
BDNF and Neuroplasticity Research
BDNF (Brain-Derived Neurotrophic Factor) is a key regulator of neuronal survival, growth, and synaptic plasticity. Preclinical research has consistently observed apparent upregulation of BDNF following Semax administration, which has made it a subject of interest in neuroplasticity and cognitive research.
Research has also examined Semax's apparent effects on the dopaminergic system. Studies in rodent models have observed apparent modulation of dopamine receptor expression and dopamine turnover, which may contribute to the observed cognitive effects in preclinical models.
Nasal Spray Research
Semax is available from PeptideIQ in a 50mg/20ml nasal spray formulation. Research has examined the nasal route of administration for peptides as a potential method of bypassing the blood-brain barrier via the olfactory pathway. Preclinical studies have observed apparent CNS activity following intranasal Semax administration in rodent models.
Research Supply in Australia
PeptideIQ supplies research-grade Semax in Australia in both lyophilised powder and nasal spray formats. Third-party HPLC tested, ≥98% purity, with full Certificate of Analysis. Express delivery Australia-wide. For laboratory research use only.
Frequently Asked Questions
What is the difference between Semax and Selank?
Semax is derived from ACTH and has been primarily studied for cognitive enhancement and neuroprotection. Selank is derived from tuftsin and has been primarily studied for anxiolytic and immune-modulating effects. Both are available from PeptideIQ for research use.
Is Semax available as a nasal spray in Australia?
PeptideIQ supplies Semax in a 50mg/20ml nasal spray format for laboratory research use only. It is not TGA-approved for human use in Australia.
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.